- Supported exchanges /
- F /
- 214.F
ANEBULO PHARMAC. DL-001 (214 F) stock market data APIs
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
ANEBULO PHARMAC. DL-001 Financial Data Overview
| 1.72 | |
| 1.67 | |
| - | |
| 1.73 | |
| 1.67 | |
| 1.57-2.88 | |
| 45 136 K | |
| 25 933 K | |
| 0 | |
| -1.59 | |
| -1.016 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ANEBULO PHARMAC. DL-001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share -0.3
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ANEBULO PHARMAC. DL-001 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.03
Get ANEBULO PHARMAC. DL-001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
